| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (1995) 35, 363-371
© 1995 The British Society for Antimicrobial Chemotherapy
review-article |
Predicting the efficacy of antimicrobial agents in respiratory infections—is tissue concentration a valid measure?
Microbiology Department-Bichat-Claude Bernard University Hospital 46 Rue Henri-Huchard, 75877 Paris Cedex 18, France
Received 13 July 1994; accepted 19 October 1994
Despite methodological and interpretive problems associated with studies of antibiotic concentrations in tissues, it is important to confirm the presence of a drug in significant concentrations in tissues and fluids at a particular site. For antibiotics used in the treatment of community-acquired respiratory infections, tissue distribution at sites of potential infection in the respiratory tree has been related to clinical outcome. Measurement of antibiotic concentrations achieved in lung parenchyma epithelial lining fluid, bronchial mucosa or bronchial secretions has indicated significant levels for ß-lactams and macrolides. Many respiratory infections are caused by obligate or facultative intracellular pathogens, which may be eradicated as a result of intracellular penetration and accumulation of macrolides, as shown in several modelsof phagocytic cells, and of intracellular antibacterial activities. For bacterial infections located in extracellular pulmonary sites, a knowledge of achievable concentrations of ß-Mactam and of macrolides should be of value. For bacteria multiplying in alveolar macrophages the high concentrations of the new macrolides that can be achieved in extravascular and intracellular fluids should have clinical relevance, as shown in this review. Moreover with newer macrolides one may expect a better patient compliance due to prolonged persistence of drug in tissues and cells which results in shorter duration of treatment and once-daily dose administration. Finally, for some sites of infection and particularly in the human respiratory tree, there is a clear relationship between local concentrations and clinical efficacy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Panidis, S. L. Markantonis, E. Boutzouka, S. Karatzas, and G. Baltopoulos Penetration of Gentamicin Into the Alveolar Lining Fluid of Critically Ill Patients With Ventilator-Associated Pneumonia Chest, August 1, 2005; 128(2): 545 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Burkhardt, J. Majcher-Peszynska, K. Borner, R. Mundkowski, B. Drewelow, H. Derendorf, and T. Welte Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery J. Clin. Pharmacol., June 1, 2005; 45(6): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Muller-Serieys, J. Andrews, F. Vacheron, and C. Cantalloube Tissue kinetics of telithromycin, the first ketolide antibacterial J. Antimicrob. Chemother., February 1, 2004; 53(2): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Namour, E. Sultan, M. H. Pascual, and B. Lenfant Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration J. Antimicrob. Chemother., June 1, 2002; 49(6): 1035 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Byl, F. Jacobs, I. Roucloux, P. de Franquen, M. Cappello, and J.-P. Thys Penetration of Meropenem in Lung, Bronchial Mucosa, and Pleural Tissues Antimicrob. Agents Chemother., March 1, 1999; 43(3): 681 - 682. [Abstract] [Full Text]
|
|